NovaSight Ltd.

NovaSight Ltd. specializes in pediatric vision assessment technology. Its primary device, CureSight, combines eye-tracking technology with data analytics to evaluate visual function in children. This is particularly useful for assessing children who may struggle to communicate their visual experiences directly, such as those with developmental or communication challenges.

NovaSight Ltd. is based in Israel. The company’s devices, including CureSight, are classified under EU Class IIa, which indicates a moderate risk level requiring compliance with specific regulatory requirements to ensure safety and performance.

Yes, NovaSight’s devices are registered in the EUDAMED database, which is the European Union’s central registry for medical devices. This listing ensures transparency and allows stakeholders to verify the device’s regulatory status within the EU market.

The CureSight device leverages advanced eye-tracking technology paired with data analytics to provide objective, automated assessments of pediatric vision. Unlike traditional methods that may rely on subjective observations or manual testing, CureSight offers a non-invasive, technology-driven approach to evaluate visual function, particularly in children who may not be able to respond verbally or through conventional methods.